



## GBT to Announce First Quarter 2021 Financial Results on Wednesday, May 5, 2021

April 28, 2021

**SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE)** -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021, after U.S. financial markets close.

Management will host a conference call on Wednesday, May 5, 2021, at 4:30 p.m. ET to provide a general business update and to discuss first quarter 2021 financial results. To participate in the conference call, please dial 877-407-3982 (domestic) or 201-493-6780 (international). A live audio webcast of the conference call can be accessed on GBT's website at [www.gbt.com](http://www.gbt.com) under the Investors section. An archived audio webcast will be available for one month following the event.

### About Global Blood Therapeutics

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta<sup>®</sup> (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit [www.gbt.com](http://www.gbt.com) and follow the company on Twitter [@GBT\\_news](https://twitter.com/GBT_news).

### Contact:

Steven Immergut (media)  
650.410.3258  
[simmergut@gbt.com](mailto:simmergut@gbt.com)

Courtney Roberts (investors)  
650.351.7881  
[croberts@gbt.com](mailto:croberts@gbt.com)



Source: Global Blood Therapeutics, Inc.